Released: 9/30/2009
Expires: 9/30/2010
Statement of Need
The purpose of this activity is to enhance knowledge concerning the treatment of patients with multiple myeloma (MM).

Target Audience
This activity was developed for pharmacists involved in the treatment and management of patients with MM.

Learning Objectives
At the completion of this activity participants should be able to:

• Identify new therapeutic options for the treatment of patients with MM
• Describe strategies for the retreatment of relapsed MM patients
• Discuss role(s) the oncology pharmacist has in the overall management of the MM patient

Registered Pharmacy Designation
MLI is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Completion of this activity provides for 1.0 contact hour (0.1 CEU) of continuing education credit. The universal program number for this activity is 468-999-09-026-H01-P.

Instructions for Credit
There is no fee for this activity. To receive credit, participants must first take the pretest for this activity. After reading this CE activity in its entirety, participants must complete the posttest and evaluation. The pretest, posttest, and evaluation can be completed online at www.mlicme.org/p09021.html. Upon completion of the evaluation and scoring a 70% or better on the posttest, you will immediately receive your certificate online. If you do not achieve a score of 70% or better on the posttest, you will be asked to take it again. Please retain a copy of the Certificate for your records.

For questions regarding the accreditation of this activity, please contact Medical Learning Institute at (609) 333-1693 or cgusack@mlicme.org.

Disclosure Statement
Before the activity, all faculty and anyone who is in a position to have control over the content of this activity will disclose the existence of any financial interest and/or relationship(s) they might have with the manufacturer(s) of any commercial products(s) to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers’ bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by MLI for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Name of Planner or Manager	Company	Reported Financial Relationship
Nancy Nesser, PharmD, JD	MLI	Nothing to disclose
Elizabeth Cohen	COEXM	Nothing to disclose

Faculty Disclosures
*Jonathan Kaufman, MD, is a consultant for Celgene and Millennium.

Beth Faiman, RN, MSN, APRN, BC, AOCN is on the speaker's bureau for Millennium and Celgene.

Stephanie Taber, PharmD, BCOP has nothing to disclose.

James O. Armitage, MD is a consultant for Allos, Eisai, Seattle Genetics, and Ziopharm.

*Jonathan Kaufman, MD, is a consultant for Celgene and Millennium.

Beth Faiman, RN, MSN, APRN, BC, AOCN is on the speaker's bureau for Millennium and Celgene.


*Content will include non-FDA-approved uses.

Disclaimer
The information provided in this CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition.